<div class="table-responsive">
    <table class="table table-striped table-hover">
        <thead>
            <tr>
                
                <th scope="col">
                    <a href="?cresstrial=12163&amp;modal=1&amp;valnames=arms&amp;order=created_at">Created at</a>
                </th>
                <th scope="col">Source</th>
                
                <th scope="col">Raw Value</th>
                <th scope="col">Validated value</th>
            </tr>
        </thead>
        <tbody>
            
            <tr class="histvalue-row" histvalueid="418506" class="table-">
                
                <td>July 7, 2022, 1:30 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Single Dose ;Injections; Intramuscular;Administration; Intranasal;Nasal Sprays;Instillation; Drug ;CIGB-669;     \r  CIGB-66; \r  MAMBISA; \r  ABDALA;Stage IGroup A: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).Group B: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L drops by nasal route; 2 drops in each nostril; single dose (Mambisa group).Group C: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L Cuban prototype spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).Stage IIMambisa Group: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L of the variant selected by nasal route; single dose (Mambisa group).Abdala Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group A: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group B: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L drops by nasal route; 2 drops in each nostril; single dose (Mambisa group).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group C: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L Cuban prototype spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).Stage IIMambisa Group: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L of the variant selected by nasal route; single dose (Mambisa group).Abdala Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;spray by nasal route, 1 shot in each nostril&quot;, &quot;treatment_id&quot;: 1976, &quot;treatment_name&quot;: &quot;Cigb-669&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;nasal route, 2 drops in each nostril&quot;, &quot;treatment_id&quot;: 1976, &quot;treatment_name&quot;: &quot;Cigb-669&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;Stage II &quot;, &quot;treatment_id&quot;: 1976, &quot;treatment_name&quot;: &quot;Cigb-669&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;Stage II intramuscular&quot;, &quot;treatment_id&quot;: 1976, &quot;treatment_name&quot;: &quot;Cigb-669&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="415210" class="table-">
                
                <td>June 23, 2022, 2 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Stage IGroup A: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).Group B: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L drops by nasal route; 2 drops in each nostril; single dose (Mambisa group).Group C: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L Cuban prototype spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).Stage IIMambisa Group: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L of the variant selected by nasal route; single dose (Mambisa group).Abdala Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Single Dose ;Injections; Intramuscular;Administration; Intranasal;Nasal Sprays;Instillation; Drug ;CIGB-669;     \r  CIGB-66; \r  MAMBISA; \r  ABDALA&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group A: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group B: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L drops by nasal route; 2 drops in each nostril; single dose (Mambisa group).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group C: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L Cuban prototype spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).Stage IIMambisa Group: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L of the variant selected by nasal route; single dose (Mambisa group).Abdala Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Single Dose ;Injections; Intramuscular;Administration; Intranasal;Nasal Sprays;Instillation; Drug ;CIGB-669;     \r  CIGB-66; \r  MAMBISA; \r  ABDALA&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;spray by nasal route, 1 shot in each nostril, single dose (Mambisa group)&quot;, &quot;treatment_id&quot;: 1976, &quot;treatment_name&quot;: &quot;Cigb-669&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;drops by nasal route, 2 drops in each nostril, single dose (Mambisa group)&quot;, &quot;treatment_id&quot;: 1976, &quot;treatment_name&quot;: &quot;Cigb-669&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;Cuban prototype spray by nasal route, 1 shot in each nostril, single dose (Mambisa group)&quot;, &quot;treatment_id&quot;: 1976, &quot;treatment_name&quot;: &quot;Cigb-669&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;by intramuscular route, in the deltoid region, single dose (Abdala group)&quot;, &quot;treatment_id&quot;: 1975, &quot;treatment_name&quot;: &quot;Cigb-66&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;Stage II Mambisa Group: of the variant selected by nasal route, single dose (Mambisa group)&quot;, &quot;treatment_id&quot;: 1976, &quot;treatment_name&quot;: &quot;Cigb-669&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 1975, &quot;treatment_name&quot;: &quot;Cigb-66&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="414300" class="table-">
                
                <td>June 17, 2022, 12:30 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Single Dose ;Injections; Intramuscular;Administration; Intranasal;Nasal Sprays;Instillation; Drug ;CIGB-669;     \r  CIGB-66; \r  MAMBISA; \r  ABDALA;Stage IGroup A: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).Group B: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L drops by nasal route; 2 drops in each nostril; single dose (Mambisa group).Group C: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L Cuban prototype spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).Stage IIMambisa Group: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L of the variant selected by nasal route; single dose (Mambisa group).Abdala Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group A: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group B: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L drops by nasal route; 2 drops in each nostril; single dose (Mambisa group).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group C: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L Cuban prototype spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).Stage IIMambisa Group: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L of the variant selected by nasal route; single dose (Mambisa group).Abdala Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;by nasal route, 1 shot in each nostril, single dose&quot;, &quot;treatment_id&quot;: 1976, &quot;treatment_name&quot;: &quot;Cigb-669&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;by nasal route, 2 drops in each nostril, single dose&quot;, &quot;treatment_id&quot;: 1976, &quot;treatment_name&quot;: &quot;Cigb-669&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;the variant selected by nasal route, single dose&quot;, &quot;treatment_id&quot;: 1976, &quot;treatment_name&quot;: &quot;Cigb-669&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;by intramuscular route, in the deltoid region, single dose&quot;, &quot;treatment_id&quot;: 1975, &quot;treatment_name&quot;: &quot;Cigb-66&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="254409" class="table-">
                
                <td>July 16, 2021, 2 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Stage IGroup A: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).Group B: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L drops by nasal route; 2 drops in each nostril; single dose (Mambisa group).Group C: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L Cuban prototype spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).Stage IIMambisa Group: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L of the variant selected by nasal route; single dose (Mambisa group).Abdala Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Single Dose ;Injections; Intramuscular;Administration; Intranasal;Nasal Sprays;Instillation; Drug ;CIGB-669;     \n  CIGB-66; \n  MAMBISA; \n  ABDALA&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group A: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group B: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L drops by nasal route; 2 drops in each nostril; single dose (Mambisa group).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group C: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L Cuban prototype spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).Stage IIMambisa Group: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L of the variant selected by nasal route; single dose (Mambisa group).Abdala Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Single Dose ;Injections; Intramuscular;Administration; Intranasal;Nasal Sprays;Instillation; Drug ;CIGB-669;     \n  CIGB-66; \n  MAMBISA; \n  ABDALA&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L;1;Nose (spray)\n&quot;, &quot;treatment_id&quot;: 1976, &quot;treatment_name&quot;: &quot;Cigb-669&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L;1;Nose (drop)\n&quot;, &quot;treatment_id&quot;: 1976, &quot;treatment_name&quot;: &quot;Cigb-669&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L;1;Nose (Cuban prototype spray)\n&quot;, &quot;treatment_id&quot;: 1976, &quot;treatment_name&quot;: &quot;Cigb-669&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0,30 mg)/0,5 mL;1;IM\n&quot;, &quot;treatment_id&quot;: 1975, &quot;treatment_name&quot;: &quot;Cigb-66&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}]
        </p>
        
    
                </td>
            </tr>
            
        </tbody>
    </table>
</div>
Created at	Source	Raw Value	Validated value
July 7, 2022, 1:30 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Single Dose ;Injections; Intramuscular;Administration; Intranasal;Nasal Sprays;Instillation; Drug ;CIGB-669; \r CIGB-66; \r MAMBISA; \r ABDALA;Stage IGroup A: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).Group B: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L drops by nasal route; 2 drops in each nostril; single dose (Mambisa group).Group C: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L Cuban prototype spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).Stage IIMambisa Group: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L of the variant selected by nasal route; single dose (Mambisa group).Abdala Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group A: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group B: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L drops by nasal route; 2 drops in each nostril; single dose (Mambisa group).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group C: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L Cuban prototype spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).Stage IIMambisa Group: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L of the variant selected by nasal route; single dose (Mambisa group).Abdala Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "spray by nasal route, 1 shot in each nostril", "treatment_id": 1976, "treatment_name": "Cigb-669", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "nasal route, 2 drops in each nostril", "treatment_id": 1976, "treatment_name": "Cigb-669", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Stage II ", "treatment_id": 1976, "treatment_name": "Cigb-669", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Stage II intramuscular", "treatment_id": 1976, "treatment_name": "Cigb-669", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]
June 23, 2022, 2 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Stage IGroup A: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).Group B: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L drops by nasal route; 2 drops in each nostril; single dose (Mambisa group).Group C: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L Cuban prototype spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).Stage IIMambisa Group: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L of the variant selected by nasal route; single dose (Mambisa group).Abdala Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Single Dose ;Injections; Intramuscular;Administration; Intranasal;Nasal Sprays;Instillation; Drug ;CIGB-669; \r CIGB-66; \r MAMBISA; \r ABDALA", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group A: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group B: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L drops by nasal route; 2 drops in each nostril; single dose (Mambisa group).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group C: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L Cuban prototype spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).Stage IIMambisa Group: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L of the variant selected by nasal route; single dose (Mambisa group).Abdala Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Single Dose ;Injections; Intramuscular;Administration; Intranasal;Nasal Sprays;Instillation; Drug ;CIGB-669; \r CIGB-66; \r MAMBISA; \r ABDALA", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "spray by nasal route, 1 shot in each nostril, single dose (Mambisa group)", "treatment_id": 1976, "treatment_name": "Cigb-669", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "drops by nasal route, 2 drops in each nostril, single dose (Mambisa group)", "treatment_id": 1976, "treatment_name": "Cigb-669", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Cuban prototype spray by nasal route, 1 shot in each nostril, single dose (Mambisa group)", "treatment_id": 1976, "treatment_name": "Cigb-669", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "by intramuscular route, in the deltoid region, single dose (Abdala group)", "treatment_id": 1975, "treatment_name": "Cigb-66", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Stage II Mambisa Group: of the variant selected by nasal route, single dose (Mambisa group)", "treatment_id": 1976, "treatment_name": "Cigb-669", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 1975, "treatment_name": "Cigb-66", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]
June 17, 2022, 12:30 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Single Dose ;Injections; Intramuscular;Administration; Intranasal;Nasal Sprays;Instillation; Drug ;CIGB-669; \r CIGB-66; \r MAMBISA; \r ABDALA;Stage IGroup A: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).Group B: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L drops by nasal route; 2 drops in each nostril; single dose (Mambisa group).Group C: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L Cuban prototype spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).Stage IIMambisa Group: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L of the variant selected by nasal route; single dose (Mambisa group).Abdala Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group A: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group B: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L drops by nasal route; 2 drops in each nostril; single dose (Mambisa group).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group C: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L Cuban prototype spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).Stage IIMambisa Group: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L of the variant selected by nasal route; single dose (Mambisa group).Abdala Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "by nasal route, 1 shot in each nostril, single dose", "treatment_id": 1976, "treatment_name": "Cigb-669", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "by nasal route, 2 drops in each nostril, single dose", "treatment_id": 1976, "treatment_name": "Cigb-669", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "the variant selected by nasal route, single dose", "treatment_id": 1976, "treatment_name": "Cigb-669", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "by intramuscular route, in the deltoid region, single dose", "treatment_id": 1975, "treatment_name": "Cigb-66", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]
July 16, 2021, 2 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Stage IGroup A: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).Group B: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L drops by nasal route; 2 drops in each nostril; single dose (Mambisa group).Group C: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L Cuban prototype spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).Stage IIMambisa Group: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L of the variant selected by nasal route; single dose (Mambisa group).Abdala Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Single Dose ;Injections; Intramuscular;Administration; Intranasal;Nasal Sprays;Instillation; Drug ;CIGB-669; \n CIGB-66; \n MAMBISA; \n ABDALA", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group A: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group B: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L drops by nasal route; 2 drops in each nostril; single dose (Mambisa group).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group C: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L Cuban prototype spray by nasal route; 1 shot in each nostril; single dose (Mambisa group).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).Stage IIMambisa Group: Vaccine candidate CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L of the variant selected by nasal route; single dose (Mambisa group).Abdala Group D: Vaccine candidate CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0;30 mg)/0;5 mL by intramuscular route; in the deltoid region; single dose (Abdala group).;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Single Dose ;Injections; Intramuscular;Administration; Intranasal;Nasal Sprays;Instillation; Drug ;CIGB-669; \n CIGB-66; \n MAMBISA; \n ABDALA", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L;1;Nose (spray)\n", "treatment_id": 1976, "treatment_name": "Cigb-669", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L;1;Nose (drop)\n", "treatment_id": 1976, "treatment_name": "Cigb-669", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "CIGB-669 (RBD 50 \u00b5g + 40 \u00b5g de HBcAg)/200 \u00b5L;1;Nose (Cuban prototype spray)\n", "treatment_id": 1976, "treatment_name": "Cigb-669", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "CIGB-66 (RBD 50 \u00b5g + Aluminum hydroxide 0,30 mg)/0,5 mL;1;IM\n", "treatment_id": 1975, "treatment_name": "Cigb-66", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]